163,997 Shares in AnaptysBio, Inc. (NASDAQ:ANAB) Acquired by Walleye Capital LLC

Walleye Capital LLC bought a new stake in shares of AnaptysBio, Inc. (NASDAQ:ANAB) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 163,997 shares of the biotechnology company’s stock, valued at approximately $5,494,000. Walleye Capital LLC owned about 0.54% of AnaptysBio at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Values First Advisors Inc. purchased a new position in shares of AnaptysBio during the third quarter valued at approximately $49,000. nVerses Capital LLC grew its position in AnaptysBio by 700.0% in the 3rd quarter. nVerses Capital LLC now owns 1,600 shares of the biotechnology company’s stock worth $54,000 after purchasing an additional 1,400 shares during the period. Headlands Technologies LLC grew its position in AnaptysBio by 444.8% in the 2nd quarter. Headlands Technologies LLC now owns 3,552 shares of the biotechnology company’s stock worth $89,000 after purchasing an additional 2,900 shares during the period. China Universal Asset Management Co. Ltd. raised its stake in AnaptysBio by 81.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,808 shares of the biotechnology company’s stock valued at $195,000 after buying an additional 2,600 shares during the last quarter. Finally, Virtu Financial LLC bought a new position in shares of AnaptysBio during the 1st quarter valued at $222,000.

Insider Buying and Selling at AnaptysBio

In other news, CFO Dennis Mulroy sold 12,220 shares of the stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $39.91, for a total transaction of $487,700.20. Following the completion of the transaction, the chief financial officer now directly owns 4,744 shares in the company, valued at approximately $189,333.04. This represents a 72.03 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Eric J. Loumeau sold 8,720 shares of the business’s stock in a transaction on Monday, September 16th. The stock was sold at an average price of $39.82, for a total transaction of $347,230.40. Following the completion of the sale, the insider now owns 7,020 shares in the company, valued at $279,536.40. This represents a 55.40 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 22,440 shares of company stock valued at $892,936 in the last 90 days. Insiders own 33.70% of the company’s stock.

Wall Street Analysts Forecast Growth

ANAB has been the subject of a number of research reports. Guggenheim upped their price objective on AnaptysBio from $75.00 to $90.00 and gave the company a “buy” rating in a research report on Monday, October 21st. JPMorgan Chase & Co. reduced their price target on shares of AnaptysBio from $75.00 to $66.00 and set an “overweight” rating for the company in a research report on Tuesday, November 12th. HC Wainwright dropped their price objective on shares of AnaptysBio from $55.00 to $52.00 and set a “buy” rating on the stock in a report on Wednesday, November 6th. Wedbush reaffirmed an “outperform” rating and set a $42.00 target price on shares of AnaptysBio in a report on Thursday, November 14th. Finally, UBS Group lifted their price target on shares of AnaptysBio from $23.00 to $33.00 and gave the stock a “neutral” rating in a research note on Wednesday, October 30th. Two equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $54.64.

AnaptysBio Stock Down 0.6 %

NASDAQ ANAB opened at $24.96 on Monday. AnaptysBio, Inc. has a twelve month low of $13.96 and a twelve month high of $41.31. The business has a 50-day moving average price of $28.13 and a 200-day moving average price of $29.74. The firm has a market cap of $759.53 million, a price-to-earnings ratio of -4.11 and a beta of -0.24.

AnaptysBio (NASDAQ:ANAB) last released its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($1.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.72) by $0.58. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. The firm had revenue of $30.02 million for the quarter, compared to analysts’ expectations of $7.92 million. Research analysts expect that AnaptysBio, Inc. will post -6.02 EPS for the current fiscal year.

AnaptysBio Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.